INTRODUCTION
The extracellular matrix of articular cartilage is rich in the aggregating proteoglycan aggrecan. This molecule is characterized by its ability to interact with hyaluronic acid and its abundant content of chondroitin sulphate and keratan sulphate chains [1] . The structure of aggrecan isolated from the cartilage matrix is not constant throughout the life of an organism, but changes due to a combination of synthetic and degradative events [2] . Most notable amongst these is the increased abundance of keratan sulphate and the decreased size of the core protein with age. Analysis of human aggrecan at the cDNA level has revealed that the primary translation product possesses a core protein of at least 2316 amino acids, which may be divided into a series of distinct domains by virtue of their sequence identity with other proteins [3] . Visualization of aggrecan by rotary shadowing has shown that these domains form a series of globular and extended regions [4] . Two globular regions, termed GI and G2, are present near the N-terminus of the core protein, and one, termed G3, is present near the Cterminus. The globular domains maintain their conformation by the presence of numerous disulphide bonds [5] . A long extended region exists between the G2 and G3 regions and this forms the principal site of attachment for the glycosaminoglycan chains. During ageing, proteolytic processing may occur in the extended domains of the aggrecan molecule, which results in loss of those fragments containing the G2 and G3 regions from the tissue and the accumulation of smaller proteoglycans bearing the GI domain [2, 6] .
The general features of the aggrecan core protein appear to be common to a variety of species [7] [8] [9] , particularly in the domains which form the globular regions. However, there does appear to be species variation within the large extended domain between the G2 and G3 regions [3, 7, 10] , and this may contribute to species variations in the degree to which the mature proteoglycans are substituted by chondroitin sulphate and keratan sulphate chondrocytes. In contrast, the neighbouring complement regulatory protein (CRP)-like domain was predominantly expressed irrespective of age, but cell culture did result in variation of the splicing ofthis domain. Versican possesses two EGF-like domains and one CRP-like domain, but at all ages the three domains were predominantly present in all transcripts. This situation persisted upon culture and passage of the chondrocytes. Thus, unlike aggrecan, the versican expressed by human articular cartilage does not appear to undergo alternative splicing of its C-terminal globular region, either in cartilage in situ or in chondrocytes in culture.
chains. In the human and the rat, the aggrecan gene is composed of 15 exons, with each exon apparently coding for a distinct structural domain [1 1] . Of particular interest is the G3 region, which is the product of five exons. Two of these exons code for domains showing sequence similarity with epidermal growth factor (EGF) and a complement regulatory protein (CRP). These exons appear to undergo alternative splicing, and may be either present or absent from the mRNA transcripts [3, 12] . In the mRNA isolated from juvenile human chondrocytes, the predominant aggrecan message is reported to lack both the EGFlike and the CRP-like domains. Aggrecan molecules possessing the EGF-like domain have been identified in the articular cartilage matrix [13] .
The aggregation potential of aggrecan is based on the presence of tile GI region. Other matrix macromolecules having the ability to interact with hyaluronate also possess an analogous region. This has been most extensively studied in link protein [14, 15] , where it has been shown that one domain is responsible for interaction with aggrecan and adjacent tandemly repeated domains are responsible for interaction with hyaluronic acid [16, 17] . Each domain is the product of a distinct exon in the link protein gene [18] . Perhaps surprisingly, the G2 region of aggrecan also contains related hyaluronate-binding domains, yet it shows no interaction with hyaluronate [19] . The large fibroblast proteoglycan versican also bears a GI region analogous to that in aggrecan, though it lacks the G2 region found in the latter [20, 21] . Versican also bears a G3 region, which differs from that of aggrecan in having tandem EGF-like domains. To date, it is not known whether alternative splicing also gives rise to G3 heterogeneity in versican. Versican also possess a long extended region separating its terminal globular regions, but unlike aggrecan this is sparsely substituted with glycosaminoglycan chains because of the low abundance of the consensus sequences necessary for the initiation of glycosylation.
The purpose of this work was: (1) Nucleotide positions for proteoglycans refer to those described in full-length cDNA sequences cited for aggrecan lacking both EGF-and CRP-like domains [3] , and versican possessing all EGFand CRP-like domains [21] . Nucleotide positions for collagens refer to those described in partial cDNA sequences including the region of COL1A2 covering the C-terminus of the collagen triple helix [24] and the 3' untranslated region of COL2A1 [25] Sequencing PCR amplified products were gel-purified using a DEAE-cellulose membrane [26] . Purified fragments were blunt-ended using the Klenow fragment of Escherichia coli DNA polymerase I and phosphorylated with bacteriophage T4 polynucleotide kinase [26] . They were then subcloned into M13 for identification by sequence analysis [26] . Sequencing was carried out using the dideoxy chain-termination method [27] and modified T7 DNA polymerase.
whether the degree of such splicing is dependent upon the procedures used for cell isolation and culture, and whether it therefore reflects the situation occurring in situ. It is also unclear whether such splicing is dependent upon the age of the individual from whom the cartilage was obtained. To address these points, RNA was extracted directly from articular cartilage and, following reverse transcription, was used to amplify the regions containing the EGF-like and CRP-like domains.
In the cartilage from subjects of various ages, from the fetus to the mature adult, transcripts were detected which either contained or did not contain the EGF-like domain. The proportions of the two variants did not appear to show any marked age-related trend, and there was always a slight predominance of transcripts lacking the EGF-like domain (Figure la ). There also appeared to be no effect of the site from which the cartilage was obtained, as the ratio of the two transcripts was independent of the depth from the articular surface of the cartilage from which the RNA was isolated (Figure lb) . Furthermore, there was no major change in the ratio of the two transcripts upon isolation of the chondrocytes from the cartilage matrix or their subsequent growth in cell culture prior to RNA isolation (Figure lc) .
The cartilage RNA preparations also showed no marked agerelated variation in expression of the CRP-like domain. At all ages studied, transcripts containing this domain were by far the major species present (Figure 2a) . Again, there was no variation observed when the cartilage was sampled at different depths from the articular surface (Figure 2b ). In contrast to the EGF-like domain, splicing of the CRP-like domain was significantly affected by chondrocyte isolation and culture. In both primary culture and passaged cells there was considerable expression of the transcripts lacking the CRP-like domain, although those transcripts possessing the CRP-like domain were still more abundant under the conditions used (Figure 2c) 
RESULTS Aggrecan
The mRNA encoding aggrecan isolated from human chondrocytes shows sequence heterogeneity in its translated region due to alternative splicing of EGF-like and CRP-like domains [3, 12] . However, it is not clear from this previous work In all experiments, RNA isolated from a long-term-cultured fibroblast cell line was used as a control in which no aggrecan mRNA was expected. Perhaps surprisingly, amplification of the reverse-transcribed DNA from the fibroblast RNA preparation readily exhibited products having the same size as those obtained for the cartilage aggrecan (Figures lc and 2c ). Isolation and sequencing of these components verified that they were indeed derived from fibroblast aggrecan mRNA. Unlike the cartilageor chondrocyte-derived aggrecan mRNA, the fibroblast mRNA showed little evidence for the presence of an EGF-like domain (Figure lc) . In contrast, with respect to the CRP-like domain, the fibroblast mRNA showed a similar splicing pattern to that obtained from cultured chondrocytes (Figure 2c ).
Versican
The identification of aggrecan mRNA as a product of fibroblasts led us to wonder whether the large fibroblast proteoglycan versican [21] might also be expressed by chondrocytes, and whether its EGF-like and CRP-like domains might also be subject to alternative splicing that could vary with culture or cell of origin. Expression of versican mRNA by human articular cartilage in situ was demonstrated using direct tissue extracts and PCR amplification with oligonucleotide primers in the region adjacent to the GI globular domain. Versican transcripts could be detected in cartilage from subjects of all ages from the fetus to the mature adult (Figure 3a) . Transcript levels appeared to be reduced in the adult cartilage, though this may reflect variation in extraction rather than a true age-related variation in abundance. Following isolation and culture of the chondrocytes, versican mRNA expression was maintained (Figure 3b ). Isolation and sequence analysis of the cartilage and chondrocyte products confirmed that they were indeed derived from versican and not through mispriming on the aggrecan transcripts.
While aggrecan possesses only one EGF-like domain, versican may possess two such domains [21] , giving rise to the possibility of three different transcripts if alternative splicing occurs in a manner analogous to that with aggrecan. However, upon amplification of the region of versican containing the EGF-like domains by PCR, only a single product was observed, irrespective of whether the original RNA was extracted directly from cartilage (Figure 4a) and 5b) . As with the versican EGF-like domains, the versican CRP-like domain was always present. The identity of these products as derivatives of versican was verified by isolation and sequencing. Similar verification was performed for the products containing the versican EGF-like domains. Estimation of mRNA levels following PCR can be misleading, as the degree of amplification can vary with both primer and template sequence for different mRNAs in a given RNA preparation. Therefore, in an attempt to provide comparative levels of aggrecan and versican mRNAs in chondrocytes and fibroblasts, total RNA preparations were subjected to slot-blot analysis. Under the conditions used, aggrecan mRNA was detectable in preparations from both newly isolated and passaged chondrocytes with loadings approaching 0.1 ug of RNA. In contrast, aggrecan message could not be detected in a preparation from cultured skin fibroblasts at a loading of 10 lug of RNA (Figure 6a ). In the case of versican, mRNA was readily detectable in fibroblasts at loadings approaching 0.1 jug of RNA. It was also detectable in preparations from both newly isolated and cultured chondrocytes, although at lower relative levels than those detected in the fibroblasts (Figure 6b ). With the chondrocyte preparations used, the abundance of versican mRNA was increased in cultured cells. Thus in the first-passage cells it represented at least 10 % of the level observed in the fibroblasts, but in the newly isolated cells the level was nearer 2 %.
Collagen
Identification of versican mRNA in chondrocytes raised the question of whether these cells exhibit any other characteristics normally associated with fibroblast-like cells. One such characteristic is the expression of type I collagen. Direct extraction of cartilage yielded an RNA preparation from which a type II collagen mRNA region could be amplified in small amounts, but in which no type I collagen mRNA product could be detected. Upon placing the chondrocytes in culture, expression of type II collagen mRNA was maintained during primary culture and early passage (Figure 7a ). The expression of type I collagen (b) ... Total RNA preparations were subjected to slot-blot analysis using 32P-labelled probes specific for (a) aggrecan and (b) versican. Samples were applied in doubling dilutions, commencing with 10 jug of RNA, and were extracted from chondrocytes directly following cell isolation (C), from chondrocytes after culture to first passage (P), and from cultured skin fibroblasts (F). By analogy with the aggrecan gene, it is likely that the versican gene possesses two exons that encode EGF-like domains and one that encodes a CRP-like domain. However, there is no evidence for these domains ever being subject to alternative splicing, irrespective of whether the transcript is derived from a chondrocyte or a fibroblast. This is in marked contrast to the splicing variation in these cell types observed for the aggrecan gene. We must await sequence information from aggrecan and versican genomic DNA at the relevant intron/exon junctions to determine whether this may explain the variation in splicing between the two molecules.
At first sight, it is somewhat surprising that both aggrecan and versican appear to be products of chondrocytes and fibroblasts, as aggrecan is normally associated with connective tissues that are subject to compression, such as cartilage and intervertebral disc [1, 28] , and versican is associated with the other connective tissues. However, proteoglycans having a structure compatible with that of aggrecan have been identified in meniscus, tendon and sclera [29] [30] [31] . Thus, under the correct circumstances, the fibroblast-like cells of these tissues can produce an aggrecan molecule analogous to that of chondrocytes. The identification of matrix versican is less clear. The aggregating proteoglycans isolated from the aorta have a domain structure on rotary shadowing electron microscopy that is compatible with their being versican [32] , and a large chondroitin sulphate proteoglycan synthetized by osteoblasts would also appear to be versican [33] . However, the only definitive evidence for versican production as a proteoglycan comes from fibroblasts in culture [34] . With respect to cartilage, it is possible that the large non-aggregating proteoglycan extracted from bovine nasal cartilage could be derived from versican. It is large, contains relatively few chondroitin sulphate chains and is distinct from aggrecan degradation products [35] . Its inability to interact with hyaluronic acid could be due to proteolytic modification or removal of the GI domain in a manner analogous to that occurring in aggrecan with age [2] .
In relation to relative mRNA levels, it appears that fibroblast aggrecan mRNA is present at levels at least two orders of magnitude lower than that in chondrocytes, based on a slot-blot analysis. This raises the question of whether the product visualized upon PCR amplification is derived from a regulated transcription event, or represents low levels present due to illegitimate transcription [36] . Many genes may exhibit such transcription at a very low level and may not be translated by the cell. Such transcripts can, however, be used for PCR analysis [37] . Whether this is the origin of the aggrecan message observed in the present study is unclear. However, the examples provided above, indicating aggrecan synthesis by the cells of fibrous connective tissues under some circumstances, suggest that this need not necessarily be the case for all cells.
In contrast, it is less likely that illegitimate transcription accounts for the versican mRNA in human chondrocytes, as it is readily detectable by slot-blot analysis. However, its low level compared with fibroblast versican mRNA levels raises two questions. First, are low levels of mRNA characteristic of all of the cells, or do selected cells possess high levels and others none? Secondly, could the detection of versican mRNA be due to contamination from fibroblasts? At present we have no data to categorically answer either question. Preliminary studies have indicated that versican mRNA can be amplified in samples from all depths of articular cartilage, and is therefore not confined to a particular zone, such as the articular surface. However, in situ hybridization studies will be necessary to determine whether the mRNA may differ in its relative abundance between different cells. The question of fibroblast contamination is also a difficult question to address, as chondrocytes in monolayer culture readily adopt a fibroblastic phenotype. However, the inability to amplify mRNA for type I collagen from direct cartilage extracts, whereas versican mRNA can be amplified, would support a chondrocyte origin for the versican mRNA. Certainly, care was taken during dissection to wash material of synovial fluid origin from the cartilage and to dissect away any soft connective tissues, particularly from the joint margins in the specimens from young subjects.
Finally, it should be stated that the identification of aggrecan mRNA in fibroblasts and versican mRNA in chondrocytes does not necessarily imply that they are being either translated or post-translationally modified in a normal manner. Verification of such synthesis awaits the generation of a panel of antibodies specific for the core proteins of the two molecules, which can be used to recognize the relevant products in cell culture medium or tissue extracts. Irrespective of this, the ability to readily amplify aggrecan mRNA from cultured fibroblasts might prove extremely useful in the analysis of possible aggrecan gene mutations in chondrodysplasias, as the procuring of skin biopsies is considerably easier than obtaining cartilage biopsies.
